Hightide Therapeutics (hong Kong) Limited
Clinical trials sponsored by Hightide Therapeutics (hong Kong) Limited, explained in plain language.
-
Can a single pill tackle both fatty liver and diabetes?
Disease control CompletedThis trial tests an experimental oral drug called HTD1801 in adults with nonalcoholic steatohepatitis (NASH), a serious liver condition, along with liver fibrosis and type 2 diabetes or prediabetes. Participants receive either HTD1801 or a placebo to see if the drug can improve l…
Phase: PHASE2 • Sponsor: HighTide Therapeutics (Hong Kong) Limited • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can a new pill tame high cholesterol?
Disease control CompletedThis trial evaluates an experimental drug called HTD1801 in overweight or obese adults with high cholesterol. The study aims to see if the drug is safe and tolerable when taken daily at different doses, and how the body processes it. Participants are randomly assigned to receive …
Phase: PHASE1, PHASE2 • Sponsor: HighTide Therapeutics (Hong Kong) Limited • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Could a peptide injection help rebuild Insulin-Making cells?
Knowledge-focused CompletedThis early-stage trial is testing an experimental drug called HTD4010, a synthetic version of a natural peptide that may help the pancreas regenerate insulin-producing cells. The study enrolls healthy, non-diabetic volunteers to receive single ascending doses of the drug or a pla…
Phase: PHASE1 • Sponsor: HighTide Therapeutics (Hong Kong) Limited • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC
-
Could a new molecule tame a rare liver disease? early safety trial begins
Knowledge-focused CompletedThis early-stage trial tests whether a single dose of HTD1801, an experimental drug for primary sclerosing cholangitis, is safe and tolerable in healthy adults. Researchers will monitor participants for side effects and measure how the drug moves through the body. The goal is to …
Phase: PHASE1 • Sponsor: HighTide Therapeutics (Hong Kong) Limited • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC